US 11458154
Treatment of CYR61- and VEGF-mediated conditions
granted A61KA61K31/136A61K31/22
Quick answer
US patent 11458154 (Treatment of CYR61- and VEGF-mediated conditions) held by VANDA PHARMACEUTICALS INC. expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VANDA PHARMACEUTICALS INC.
- Grant date
- Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/136, A61K31/22, A61K31/351, A61K31/365